Clinical Trial

Study of IBI363 in Patients with Advanced First-line Gastric Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 20, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a phase 1b study designed to evaluate the safety, tolerability and efficacy of IBI363 in combination with oxaliplatin and capecitabine (XELOX) in first-line treatment of unresectable advanced or metastatic gastric and gastroesophageal junction adenocarcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-20.
Status change: Not Yet Recruiting → Recruiting 2024-11-18
Trial Details
NCT Number NCT06610799
Lead Sponsor Xiangdong Cheng
Conditions IBI363 + Chemotherapy
Enrollment 40 participants
Start Date 2024-10-15
Primary Completion 2025-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-20